DK3022226T3 - TARGETED MODIFIED IL-1 FAMILY MEMBERS - Google Patents
TARGETED MODIFIED IL-1 FAMILY MEMBERS Download PDFInfo
- Publication number
- DK3022226T3 DK3022226T3 DK14735574.7T DK14735574T DK3022226T3 DK 3022226 T3 DK3022226 T3 DK 3022226T3 DK 14735574 T DK14735574 T DK 14735574T DK 3022226 T3 DK3022226 T3 DK 3022226T3
- Authority
- DK
- Denmark
- Prior art keywords
- primer
- dna
- artificial sequence
- cells
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306047 | 2013-07-19 | ||
| PCT/EP2014/064283 WO2015007542A1 (en) | 2013-07-19 | 2014-07-04 | Targeted modified il-1 family members |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3022226T3 true DK3022226T3 (en) | 2019-03-25 |
Family
ID=48874235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14735574.7T DK3022226T3 (en) | 2013-07-19 | 2014-07-04 | TARGETED MODIFIED IL-1 FAMILY MEMBERS |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9932409B2 (https=) |
| EP (1) | EP3022226B1 (https=) |
| JP (1) | JP6475713B2 (https=) |
| KR (1) | KR102275090B1 (https=) |
| CN (1) | CN105612180B (https=) |
| AU (1) | AU2014292377B2 (https=) |
| BR (1) | BR112016001128A2 (https=) |
| CA (1) | CA2918518C (https=) |
| DK (1) | DK3022226T3 (https=) |
| ES (1) | ES2714504T3 (https=) |
| IL (1) | IL243466B (https=) |
| MX (1) | MX370348B (https=) |
| SG (1) | SG11201600167SA (https=) |
| WO (1) | WO2015007542A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7115982B2 (ja) | 2015-10-30 | 2022-08-09 | アレタ・バイオセラピューティクス・インコーポレイテッド | 癌の治療のための組成物及び方法 |
| KR20180083868A (ko) | 2015-10-30 | 2018-07-23 | 알레타 바이오쎄라퓨틱스, 인크. | 종양 형질도입용 조성물 및 방법 |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11001631B2 (en) | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| CN109563141A (zh) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| CA3040802A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| EP3580230B1 (en) | 2017-02-07 | 2026-04-22 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3055200A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Compositions and methods for immunotherapy |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| EP3665201A4 (en) | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| US12091463B2 (en) | 2017-08-09 | 2024-09-17 | Orionis Biosciences, Inc. | Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH) |
| CN111527109B (zh) * | 2017-12-26 | 2024-11-01 | 南京金斯瑞生物科技有限公司 | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 |
| US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| JP2021513361A (ja) | 2018-02-05 | 2021-05-27 | オリオニス バイオサイエンシーズ，インコーポレイテッド | 線維芽細胞結合物質およびその使用 |
| WO2020033646A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| CA3133648A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| CN120590542A (zh) | 2019-03-28 | 2025-09-05 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| WO2020257412A1 (en) | 2019-06-19 | 2020-12-24 | Orionis Biosciences, Inc. | Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes |
| EP4178609A4 (en) * | 2020-07-07 | 2024-07-24 | Orionis Biosciences, Inc. | IMMUNOSTIMULATORY ADJUVANTS |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2055445T3 (es) | 1989-08-22 | 1994-08-16 | Immunex Corp | Proteinas de fusion que comprenden gm-csf e il-3. |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| WO2001029870A1 (en) * | 1999-10-21 | 2001-04-26 | Sarnoff Corporation | Bi-potential electrode space-saving cathode ray tube |
| CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| WO2008014612A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| US20110038865A1 (en) * | 2007-06-26 | 2011-02-17 | University Of Miami | Antibody- endostatin fusion protein and its variants |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| US8334101B2 (en) * | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| JP2012510806A (ja) | 2008-12-08 | 2012-05-17 | コンプリクス エン ヴェー | 単鎖逆平行コイルドコイルタンパク質 |
| ES2534085T3 (es) * | 2009-08-17 | 2015-04-17 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| US20130115189A1 (en) * | 2009-09-10 | 2013-05-09 | Cytos Biotechnology Ag | Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| SG10201603411WA (en) | 2011-10-28 | 2016-07-28 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| CN104245734B (zh) | 2012-01-20 | 2017-09-05 | 非营利性组织佛兰芒综合大学生物技术研究所 | 靶向突变体α‑螺旋束细胞因子 |
| ES2800426T3 (es) | 2012-03-03 | 2020-12-30 | Immungene Inc | Moléculas de fusión anticuerpos-mutante de interferón modificadas |
-
2014
- 2014-07-04 DK DK14735574.7T patent/DK3022226T3/en active
- 2014-07-04 WO PCT/EP2014/064283 patent/WO2015007542A1/en not_active Ceased
- 2014-07-04 MX MX2016000723A patent/MX370348B/es active IP Right Grant
- 2014-07-04 BR BR112016001128-7A patent/BR112016001128A2/pt not_active Application Discontinuation
- 2014-07-04 CN CN201480040652.6A patent/CN105612180B/zh active Active
- 2014-07-04 EP EP14735574.7A patent/EP3022226B1/en active Active
- 2014-07-04 CA CA2918518A patent/CA2918518C/en active Active
- 2014-07-04 US US14/905,352 patent/US9932409B2/en active Active
- 2014-07-04 JP JP2016526518A patent/JP6475713B2/ja active Active
- 2014-07-04 AU AU2014292377A patent/AU2014292377B2/en active Active
- 2014-07-04 ES ES14735574T patent/ES2714504T3/es active Active
- 2014-07-04 KR KR1020167002679A patent/KR102275090B1/ko active Active
- 2014-07-04 SG SG11201600167SA patent/SG11201600167SA/en unknown
-
2016
- 2016-01-05 IL IL24346616A patent/IL243466B/en active IP Right Grant
-
2018
- 2018-02-21 US US15/901,545 patent/US20180186894A1/en not_active Abandoned
-
2019
- 2019-03-21 US US16/360,793 patent/US20190202934A1/en not_active Abandoned
-
2020
- 2020-04-28 US US16/860,660 patent/US20200255545A1/en not_active Abandoned
-
2023
- 2023-02-01 US US18/163,026 patent/US20230235086A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200255545A1 (en) | 2020-08-13 |
| JP6475713B2 (ja) | 2019-02-27 |
| IL243466A0 (en) | 2016-03-31 |
| IL243466B (en) | 2019-11-28 |
| KR102275090B1 (ko) | 2021-07-09 |
| US20160152730A1 (en) | 2016-06-02 |
| CA2918518C (en) | 2022-08-16 |
| US9932409B2 (en) | 2018-04-03 |
| CN105612180A (zh) | 2016-05-25 |
| MX2016000723A (es) | 2016-12-20 |
| US20180186894A1 (en) | 2018-07-05 |
| WO2015007542A1 (en) | 2015-01-22 |
| US20230235086A1 (en) | 2023-07-27 |
| AU2014292377A1 (en) | 2016-02-04 |
| EP3022226A1 (en) | 2016-05-25 |
| MX370348B (es) | 2019-12-10 |
| KR20160108293A (ko) | 2016-09-19 |
| CA2918518A1 (en) | 2015-01-22 |
| CN105612180B (zh) | 2019-11-12 |
| JP2016527221A (ja) | 2016-09-08 |
| US20190202934A1 (en) | 2019-07-04 |
| ES2714504T3 (es) | 2019-05-28 |
| BR112016001128A2 (pt) | 2018-01-23 |
| EP3022226B1 (en) | 2018-12-05 |
| SG11201600167SA (en) | 2016-02-26 |
| AU2014292377B2 (en) | 2019-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230235086A1 (en) | Targeted modified il-1 family members | |
| JP6041799B2 (ja) | Ｔｒａｉｌｒ２特異的多量体足場 | |
| EP3013859B1 (en) | Bispecific molecules capable of specifically binding to both ctla-4 and cd40 | |
| CA2411470C (en) | T cell receptor fusions and conjugates and methods of use thereof | |
| CN110461871A (zh) | 白蛋白结合结构域融合蛋白 | |
| CN107922470A (zh) | 对lag‑3和pd‑1特异性的新型融合多肽 | |
| CN108948177A (zh) | 融合分子与il-15变异体 | |
| CN110392695A (zh) | 针对cd127的抗体和多肽 | |
| KR20220127867A (ko) | 편향된 il2 뮤테인 방법 및 조성물 | |
| KR20230120139A (ko) | 재조합 cd3 결합 단백질 및 이의 용도 | |
| JP2023510871A (ja) | Ｉｌ２ムテイン | |
| JP2021527047A (ja) | 消化管系へのペイロード送達のための、ｂｔｎｌ３／８を標的とする構築物 | |
| US20240376172A1 (en) | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues | |
| US20240156980A1 (en) | Protease cleavable prodrugs | |
| HK1225048B (en) | Targeted modified il-1 family members | |
| HK1225048A1 (en) | Targeted modified il-1 family members | |
| CN117242094A (zh) | 蛋白酶可切割的前药 | |
| TW202502807A (zh) | 融合il10多肽 | |
| CN118620057A (zh) | Il-1r1胞外区多肽突变体及其用途 | |
| WO2024005204A1 (ja) | 融合タンパク質 | |
| CN111100211A (zh) | 一种Fc融合蛋白及其应用 |